J. Ritchie

Heparanase drives the aggressive myeloma phenotype: Preclinical development of a heparanase inhibitor for the treatment of multiple myeloma

J. Ritchie, 2010 .

Syndecan-1 Is Required for Robust Growth, Vascularization, and Metastasis of Myeloma Tumors in Vivo*

Y. Khotskaya, R. Sanderson, V. Macleod, 2009, The Journal of Biological Chemistry.

Heparanase promotes myeloma stemness and in vivo tumorigenesis.

R. Sanderson, Rada Amin, Vishnu C. Ramani, 2019, Matrix biology : journal of the International Society for Matrix Biology.

SST0001, a Chemically Modified Heparin, Inhibits Myeloma Growth and Angiogenesis via Disruption of the Heparanase/Syndecan-1 Axis

F. Zunino, R. Sanderson, C. Pisano, 2011, Clinical Cancer Research.

Cancer Therapy : Preclinical SST 0001 , a Chemically Modified Heparin , Inhibits Myeloma Growth and Angiogenesis via Disruption of the Heparanase / Syndecan-1 Axis

F. Zunino, R. Sanderson, C. Pisano, 2011 .

Proteoglycans and Cancer

Y. Khotskaya, A. Purushothaman, R. Sanderson, 2010 .

Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels.

D. Alberts, G. Piazza, D. Ahnen, 1997, Cancer research.